Marketing-authorisation holder · Canada
Emd Serono, A Division of Emd Inc.
65 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
65 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 65
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BAVENCIO20 mg / ml · Solution | Avelumab | Canada | Marketed | 2017 |
| CETROTIDE0.25 mg / vial · Powder For Solution | Cetrorelix | Canada | Marketed | 2004 |
| CRINONE8 % · Gel | Progesterone | Canada | Marketed | 2000 |
| GONAL-F PEN300 unit / 0.48 ml · Solution | Follitropin alfa | Canada | Marketed | 2005 |
| GONAL-F PEN450 unit / 0.72 ml · Solution | Follitropin alfa | Canada | Marketed | 2005 |
| GONAL-F PEN900 unit / 1.44 ml · Solution | Follitropin alfa | Canada | Marketed | 2005 |
| LUVERIS75 unit / vial · Powder For Solution | Lutropin alfa | Canada | Marketed | 2005 |
| MAVENCLAD10 mg · Tablet | Cladribine | Canada | Marketed | 2017 |
| OVIDREL250 mcg / 0.5 ml · Solution | Choriogonadotropin alfa | Canada | Marketed | 2004 |
| OVIDREL250 mcg / 0.5 ml · Solution | Choriogonadotropin alfa | Canada | Marketed | 2013 |
| PERGOVERIS900 unit / 1.44 ml + 450 unit / 1.44 ml · Solution | Follitropin alfa, Lutropin alfa | Canada | Marketed | 2021 |
| PERGOVERIS450 unit / 0.72 ml + 225 unit / 0.72 ml · Solution | Follitropin alfa, Lutropin alfa | Canada | Marketed | 2021 |
| PERGOVERIS300 unit / 0.48 ml + 150 unit / 0.48 ml · Solution | Follitropin alfa, Lutropin alfa | Canada | Marketed | 2021 |
| PERGOVERIS150 unit / vial + 75 unit / vial · Kit, Powder For Solution | Follitropin alfa, Lutropin alfa | Canada | Not marketed | 2015 |
| PIMJETMI25 mg · Capsule | Pimicotinib | Canada | Marketed | 2026 |
| REBIF22 mcg / 0.5 ml · Solution | Interferon beta-1a | Canada | Marketed | 1998 |
| REBIF66 mcg / 1.5 ml · Solution | Interferon beta-1a | Canada | Marketed | 2009 |
| REBIF44 mcg / 0.5 ml · Solution | Interferon beta-1a | Canada | Marketed | 1998 |
| REBIF132 mcg / 1.5 ml · Solution | Interferon beta-1a | Canada | Marketed | 2009 |
| SAIZEN5.83 mg / ml · Solution | Somatropin | Canada | Marketed | 2010 |
| SAIZEN8 mg / ml · Solution | Somatropin | Canada | Marketed | 2010 |
| SAIZEN5 mg / vial · Powder For Solution | Somatropin | Canada | Marketed | 1999 |
| SAIZEN8 mg / ml · Solution | Somatropin | Canada | Marketed | 2010 |
| SEROSTIM5 mg / kit + 1 ml / kit · Powder For Solution | Somatropin, Water | Canada | Marketed | 1999 |
| TEPMETKO225 mg · Tablet | Tepotinib | Canada | Marketed | 2021 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 65 | 25 | 40 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.